Tag Archives: public policy

Why all the negativity around National Health Insurance in South Africa?

23 Aug
National-Health-Insurance

Why all the negativity around national health insurance (NHI) in South Africa? There is so much bad news such as comments by the Solidarity Research Institute that NHI will collapse the healthcare system, the Free Market Foundation believes the NHI will be a gateway for corruption, and Alex van den Heever at Wits University thinks […]

Value-Based Pricing of New Technologies

13 Aug
price and value balance sign

Health insurance companies and governments use strong financial and administrative barriers to manage the utilization of new technologies. Cost-sharing (co-insurance or co-payments), prior authorization, clinical panel reviews, therapeutic reference pricing, and new technology appraisals are designed to manage the incremental uptake of new technologies. These technologies, for example, PCSK-9 inhibitors and enzyme replacement therapies, are […]

Market Access Landscape in the Middle East:The Next Five Years

06 Jun
Middle-East

The market access landscape in the Middle East is changing rapidly. The growth of private health insurance markets in the Gulf is a significant catalyst for the re-organisation of private sector stakeholders and improvements in internal reimbursement policies. In the past, Payors were relatively generous in their reimbursement of new technologies, but in the next […]

Is Real-World Evidence all it’s trumped-up to be?

10 Apr
multiplechro

There’s so much discussion around Big Data and Real-World Evidence (RWE) in improving access to medicines. RWE is clinical data collected after the publication of clinical trials used for marketing authorization. Sources may include health insurance claims databases, patient registries, hospital patient records, among others. Clinical trials are by design the gold standard for new […]

C&C at ISPOR in Glasgow

11 Oct
ISPOR

C&C at ISPOR in Glasgow C&C will be at ISPOR Glasgow in just a few weeks. Will you? We’re presenting results of our recent work for Clients in Sub-Saharan Africa and the Middle East. We put great effort into analysing new health technologies, determining their budget impact in various markets, and assessing market access opportunities. […]

Does the pharmaceutical industry bribe the FDA?

09 Aug
fda-logo-small

It’s not the type of question we’re asked every day, so it sparked our interest, particularly the assumption that something like this is possible. Opinion on the subject is divided. They range from ideas that anything related to the pharmaceutical industry is tainted, in this case the FDA, to opinions from scientists and policy experts […]

South Africa’s Private Health Insurance Industry: A Strategic National Asset under Threat?

11 Jul
Emergency

South Africa’s Cabinet of Ministers recently approved a White Paper on National Health Insurance aimed at moving the policy of universal health coverage further down the road. A National Health Insurance system would result in an integrated healthcare system founded on the principles of solidarity and redistribution of healthcare resources. The basic idea is that […]

WHO’s serious reservations on Value-Based Pricing: Conflicts and Nuances

08 Jun
WHO Fair Pricing Forum Carapinha & Company

On May 10 and 11, the WHO Fair Pricing Forum met to discuss improvements to medicine pricing practices and pricing approaches that balance public health needs and incentives for pharmaceutical research and development. The Forum was established to facilitate the exchange of insights on fairer medicine pricing systems, identification of research gaps to support improvements, […]

Comment on the implications of external price referencing of pharmaceuticals in Middle East countries

15 Aug

Expert Review of Pharmacoeconomics & Outcomes Research Corresponding Author: Dr. João L. Carapinha, Ph.D External Price Referencing (EPR) is frequently used by countries to control pharmaceutical prices but studies to substantiate its use in the Middle East (ME) is lacking. The paper by Kalo et al set-out to fill this lacuna through three objectives: i) […]

China’s medicine pricing pro-market reforms

07 May
china

China’s National Development and Reform Commission announced earlier this week it would lift medicine price restrictions on most medicines except narcotics and psychotropics. The decision will shift price-setting decisions from regulators to the market and the Commission hopes it will improve competition and result in lower medicine prices. It is still early days whether this policy […]

Carapinha Logo